Physician profile
Michael John Main
NPI 1649833005
$878.85
in general payments reported to CMS, 2019-2025
11 companies · $674 in 2025
The $674 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $205 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $288.66 | 2024-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $142.97 | 2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $102.62 | 2024-2025 | Cuvitru, Hyqvia |
| Amgen INC. | $81.42 | 2024-2025 | Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $68.34 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $39.42 | 2025 | |
| Grifols USA, LLC | $34.49 | 2024 | Xembify |
| Octapharma USA, INC. | $33.36 | 2025 | Cutaquig |
| Genzyme Corporation | $31.72 | 2024 | |
| Hospira, INC. | $29.74 | 2025 | |
| Arcutis Biotherapeutics, INC. | $26.11 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Main listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.